Furthermore, we detected caspase-3 levels by immunohistochemistry and by a colorimetric assay kit on tumor samples, showing that KYP2047 at doses of 2.5 and 5 mg/kg significantly increased caspase-3 activity compared to the control group (Figure 6A–C; see immunohistochemistry score Figure 6D,E. This evidence concerns the gene CASP3 and neoplasm.